Rebate ban glooms pharmaceutical industry

Prospects have been grim for Korean firms, as they are getting pressed by multinationals' increasing market presence and the government's pressure to lower drug costs. Generic drugs have long been the competitive edge for local makers, but even they are set to lose steam once doctors choose to prescribe originals over generics without kickbacks.

“Domestic manufacturers can no longer expect t...